Weekly Archive

BioHedge Weekly: Biotech Hedge Fund 13D and 13G Filing Tracker

13D/13G filings from biotech-focused institutional investors, cross-referenced with trial events and regulatory filings. Part of the RxDataLab platform with clinical trials, SEC filings, and hedge fund positioning, linked by company.

Get access Live dashboard →

RA Capital Management reduced INHIBIKASE THERAPEUTICS INC stake to 9.9% (down 6.0pp). 1 filing this week, all passive.

1 filings 1 passive (13G)

Perceptive Advisors initiated new 10.1% position in a biotech

8 filings 5 activist (13D) 3 passive (13G) 3 new positions

RA Capital Management initiated new 15.9% position in INHIBIKASE THERAPEUTICS INC

6 filings 3 activist (13D) 3 passive (13G) 2 new positions

BVF Partners L.P. initiated new 10.0% position in Pyxis Oncology, Inc.

4 filings 2 activist (13D) 2 passive (13G) 1 new position

BVF Partners L.P. reduced MoonLake Immunotherapeutics stake to 19.7% (down 2.6pp)

3 filings 3 activist (13D)

EcoR1 Capital initiated new 9.0% position in Fulcrum Therapeutics, Inc.

9 filings 7 activist (13D) 2 passive (13G) 2 new positions

RA Capital Management initiated new 23.8% position in Parabilis Medicines, Inc.

7 filings 7 activist (13D) 1 new position

RA Capital Management initiated new 5.8% position in Editas Medicine, Inc.. 1 filing this week, all passive.

1 filings 1 passive (13G) 1 new position

BVF Partners L.P. initiated new 5.3% position in a biotech

3 filings 2 activist (13D) 1 passive (13G) 1 new position

RA Capital Management initiated new 6.3% position in Sana Biotechnology, Inc.

2 filings 1 activist (13D) 1 passive (13G) 1 new position

Cormorant Asset Management, LP initiated new 7.6% position in Rallybio Corp

70 filings 8 activist (13D) 62 passive (13G) 3 new positions

EcoR1 Capital increased ATARA BIOTHERAPEUTICS INC stake to 17.4% (up 7.5pp)

7 filings 5 activist (13D) 2 passive (13G)

RA Capital Management initiated new 9.9% position in Prelude Therapeutics Inc

6 filings 3 activist (13D) 3 passive (13G) 2 new positions

Perceptive Advisors initiated new 5.4% position in SUTRO BIOPHARMA, INC.

12 filings 8 activist (13D) 4 passive (13G) 2 new positions

Perceptive Advisors initiated new 10.0% position in KIORA PHARMACEUTICALS INC

9 filings 6 activist (13D) 3 passive (13G) 2 new positions

RA Capital Management initiated new 9.9% position in OnKure, Inc.

7 filings 3 activist (13D) 4 passive (13G) 3 new positions

RA Capital Management initiated new 9.9% position in Karyopharm Therapeutics Inc.

7 filings 5 activist (13D) 2 passive (13G) 2 new positions

Baker Brothers Advisors increased Celcuity Inc. stake to 20.0% (up 1.1pp)

5 filings 5 activist (13D)

Perceptive Advisors initiated new 5.3% position in Relay Therapeutics, Inc.

4 filings 3 activist (13D) 1 passive (13G) 1 new position

Perceptive Advisors reduced Solid Biosciences Inc. stake to 12.9% (down 2.7pp)

3 filings 3 activist (13D)

Deerfield Management reduced Larimar Therapeutics, Inc. stake to 34.4% (down 1.4pp)

4 filings 4 activist (13D)

BIOS Partners reduced Lantern Pharma Inc. stake to 8.6% (down 1.4pp)

3 filings 3 activist (13D)

BVF Partners L.P. initiated new 10.0% position in IMMUNIC INC

69 filings 1 activist (13D) 68 passive (13G) 8 new positions

RA Capital Management initiated new 9.9% position in ALX Oncology Inc.

8 filings 5 activist (13D) 3 passive (13G) 1 new position

RA Capital Management initiated new 7.0% position in HELIX ACQUISITION CORP II

3 filings 3 passive (13G) 1 new position

Perceptive Advisors initiated new 7.3% position in SAB BIOTHERAPEUTICS INC

4 filings 3 activist (13D) 1 passive (13G) 1 new position